

NOUVEAU LIFE PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIALS
UNAUDITED
2016 Annual

BALANCE SHEET

ASSETS

Current	
Cash	3,577
Accounts Receivable	16,788
Fixed Asset	-
TOTAL ASSETS	<u>20,365</u>

LIABILITIES

Current	
Loan	10,000
Sales Tax Payable	2,677
Notes Payable	196,368
Total Liabilities	<u>209,045</u>

STOCKHOLDERS' EQUITY

SHARE CAPITAL	
Common shares, 4,500,000,000 authorized, par value \$0.0001 - Issued and outstanding, December 31, 2016 - 4,349,999,733	435,000
Preferred shares, 10,000,000 authorized Issued and outstanding, December 31, 2016 - 10,000,000	1,000
Accumulated Deficit	(624,680)
Shareholders net gain (loss)	<u>(188,680)</u>
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	<u>20,365</u>

NOUVEAU LIFE PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIALS
UNAUDITED
2016 Annual

BALANCE SHEET

STATEMENTS OF EARNINGS

REVENUE

Income	76,899
Cost of Sales	<u>3,542</u>
Gross Margin	<u>73,357</u>

OPERATING EXPENSES

Selling, general and administrative	85,672
Total Operating Expenses	<u>85,672</u>

NET GAIN (LOSS) (8,773)

Weighted Average Number of Common Shares	4,349,999,733
Net Loss Per Share - Basic and Fully Diluted	(0.00)

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss	\$ (8,773)
Stock issued for services rendered	-
Stock issued for cash	-
Changes in assets and liabilities	-
Accounts payable	<u>-</u>

NET CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES (8,773)

CASH FLOWS FROM FINANCING ACTIVITIES

Advances by(to) shareholder	-
Share capital issued	-

NET CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES

Cash and Cash Equivalents - beginning of quarter	1,433
Cash and Cash Equivalents - end of quarter	3,577
Net Change In Cash	5,010

NOUVEAU LIFE PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIALS
UNAUDITED
2016 Annual

BALANCE SHEET
STOCKHOLDERS' EQUITY

	Common Shares	Stock Amount	Additional Paid In Capital
Balance December 31, 2015	1,989,999,773	199,000	
Stock issued for services	2,359,999,960	236,000	
Stock issued for cash		-	
Stock issued for acquisition		-	
Balance December 31, 2016	4,349,999,733	435,000	

NOUVEAU LIFE PHARMACEUTICALS, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2016
(Unaudited)

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

a) Basis of Presentation:

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. At the balance sheet date, the Company has a stockholders' deficiency and a deficit accumulated during the development stage. Management plans to issue more shares of common stock in order to raise funds.

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles. In the opinion of management, these financial statements include all adjustments necessary in order to make them not misleading.

b) Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

c) Cash and Cash Equivalents:

For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with maturity of three months or less to be cash equivalents.

d) Income taxes:

The Company utilizes the liability method of accounting for income taxes. Under the liability method deferred tax assets and liabilities are determined based on the differences between financial reporting basis and the tax basis of the assets and liabilities and are measured using enacted tax rates and laws that will be in effect, when the differences are expected to reverse. An allowance against deferred tax assets is recognized, when it is more likely than not, that such tax benefits will not be realized.

Any deferred tax asset is considered immaterial and has been fully offset by a valuation allowance because at this time the Company believes that it is more likely than not that the future tax benefit will not be realized as the Company has no current operations.

e) Loss per Common Share:

Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.

f) Fair Value of Financial Instruments:

The carrying value of cash, due from affiliate and due to shareholder approximate their fair value due to the short period of time to maturity.

g) Comprehensive Income:

Comprehensive income (loss) is not presented in the Company's financial statements since there is no difference between net loss and comprehensive loss in any period presented.

NOTE 2 - CAPITAL STOCK

The total number of shares of capital stock, which the Company shall have authority to issue, is 4,500,000,000 shares common shares par value \$0.0001. Holders of shares of common stock are entitled to cast one vote for each share held at all stockholders' meetings for all purposes, including the election of directors. The common stock does not have cumulative voting rights.

NOTE 3 - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

We adopted the provisions of the FASB Statement on Generally Accepted Accounting Principles ("GAAP") relating to the FASB Accounting Standards Codification ("Codification") on DECEMBER 31, 2009. This Statement establishes the Codification as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP. Rules and interpretive releases of the Securities and Exchange Commission ("SEC") under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. The FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts; instead, the FASB will issue Accounting Standards Updates.

NOTE 4 - INCOME TAXES

The Company has incurred net losses and, therefore, has no tax liability. The net deferred tax asset generated by the loss carry-forward has been fully reserved.

NOTE 5 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the accompanying financial statements, the Company incurred losses since its inception and has not produced enough revenues from operations. These factors raise substantial doubt about the Company's ability to continue as a going concern.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern. Management anticipates that it will be able to raise additional working capital through the issuance of stock and through additional loans from investors.

The ability of the Company to continue as a going concern is dependent upon the Company's ability to attain a satisfactory level of profitability and obtain suitable and adequate financing. There can be no assurance that management's plan will be successful.

NOTE 6 – NOTES PAYABLE

The Company has convertible notes dated June 30, 2012, August 30, 2012 and October 15, 2012, in the amount of \$75,000, \$75,000 and \$46,368 respectively.

NOTE 7 - LACK OF INSURANCE

The Company could be exposed to liabilities or other claims for which the Company would have no insurance protection. The Company does not currently maintain any property insurance, business interruption insurance, products liability insurance, or any other comprehensive insurance policy. Any purchaser of the Company's common stock could lose their entire investment should uninsured losses occur.